Callan JMB Inc. Reports Decline in Q2 2025 Revenues to $1.7 Million, Operating Loss of $1.4 Million Amid Decreased Demand for Emergency Preparedness Services

Callan JMB Inc. has released its financial results for the second quarter of 2025. The company reported revenues of $1.7 million for the three-month period and $3.1 million for the six months ended June 30, 2025, marking a year-over-year decrease attributed to a decline in demand for emergency preparedness services by certain states and local governments. The cost of revenues for the corresponding three-month and six-month periods were $1.0 million and $1.9 million, respectively, reflecting a decrease in line with the revenue decline. Gross profit amounted to $0.6 million for the three months and $1.3 million for the six months ended June 30, 2025. The company reported a loss from operations of $1.4 million for the three months and $2.6 million for the six months ended June 30, 2025. SG&A expenses increased year-over-year to $2.0 million for the quarter and $3.9 million for the half-year, primarily due to higher consulting, professional fees, marketing expenses, and staffing costs as the company transitions to being a public entity. In terms of business updates, Callan JMB formed a strategic partnership with Revival Health Inc. to develop integrated supply chain services for health, wellness, and longevity products. The company also launched a subsidiary in India, establishing a temperature-controlled warehouse for pharmaceuticals, and extended a long-term contract with the City of Chicago, securing increased funding. Additionally, Callan JMB supported measles outbreak response efforts in Texas and New Mexico by redistributing MMR II vaccines. The company ended the quarter with $4.2 million in cash and cash equivalents and entered into an equity line of credit agreement to sell up to $25 million of shares of its common stock.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Callan JMB Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-024067), on August 14, 2025, and is solely responsible for the information contained therein.